The effect of long-term systemic immunosuppressive drug use on druse formation: a new perspective to age-related macular degeneration

Background/aim: To evaluate the effect of the long-term use of systemic immunosuppressive drugs on druse formation in patients aged over 50 years. Materials and methods: The current retrospective cohort study includes 420 eyes of 420 patients. 210 eyes of 210 patients who used immunosuppressive drugs (Group 1) at least for the last 5 years and 210 eyes of 210 control patients (Group 2) who did not use any drugs were compared. All patients were older than 50 years and selected among patients who were followed by rheumatology and ophthalmology clinic at a tertiary university hospital. All patients had complete ophthalmic examination, fundus photography and optical coherence tomography (OCT). The primary outcome of this study is the difference in macular and paramacular druse formation rates between two groups. Results: Small, intermediate, large, soft, and paramacular druse formation rates were significantly lower in Group 1 than those in Group 2 (P = 0.028, P = 0.001, P = 0.001, P = 0.001, and P = 0.001, respectively). Conclusion: Patients who used long-term systemic immunosuppressive drugs had significantly lower hard and soft druse formation rate than age and sex matched control subjects.

PDF

___

1. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004; 122 (4): 564-572. doi: 10.1001/archopht.122.4.564
2. Wong WL, Su X, Li X, Cheung CM, Klein R et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health 2014; 2 (2): 106-116. doi: 10.1016/S2214-109X(13)70145-1 2: 106–116
3. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. American Journal of Ophthalmology 2002; 134 (3): 411-431. doi: 10.1016/s0002-9394(02)01624-0
4. Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch’s membrane, and retinal pigment epithelium in postmortem eyes with agerelated macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Survey of Ophthalmology 1999; 44 (1): S10-S32. doi: 10.1016/s0039- 6257(99)00086-7
5. Li CM, Chung BH, Presley JB, Malek G, Zhang X et al. Lipoprotein-like particles and cholesteryl esters in human Bruch’s membrane: initial characterization. Investigative Ophthalmology & Visual Science 2005; 46 (7): 2576-2586. doi: 10.1167/iovs.05-0034
6. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proceedings of the National Academy of Sciences of the USA 2002; 99 (23): 14682-14687. doi: 10.1073/pnas.222551899
7. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Experimantal Eye Research 2001; 73 (6): 887-896. doi: 10.1006/ exer.2001.1094
8. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Federation of American Societies for Experimental Biology 2000; 14 (7): 835-846.
9. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G et al. The International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Survey of Ophthalmology 1995; 39 (5): 367-374. doi: 10.1016/s0039- 6257(05)80092-x
10. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to agerelated macular degeneration. Proceedings of the National Academy of Sciences of the USA 2005; 102 (20): 7227-7232. doi: 10.1073/pnas.0501536102
11. Kanda A, Chen W, Othman M, Branham KE, Brooks M et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proceedings of the National Academy of Sciences of the USA 2007; 104 (41): 16227-16232. doi: 10.1073/ pnas.0703933104
12. Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nature Genetics 2008; 40 (7): 892-896. doi: 10.1038/ng.170
13. Micklisch S, Lin Y, Jacob S, Karlstetter M, Dannhausen K et al. Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activator. Journal of Neuroinflammation 2017; 14 (4). doi: 10.1186/s12974-016-0776-3
14. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH et al. Individuals homozygous for the age-related macular degeneration risk- conferring variant of complement factor H have elevated levels of CRP in the choroid. Proceedings of the National Academy of Sciences of the USA 2006; 103 (46): 17456-17461. doi: 10.1073/pnas.0606234103
15. Seddon JM, Gensler G, Rosner B. C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology 2010; 117 (8): 1560-1566. doi: 10.1016/j.ophtha.2009.11.020
16. Chew EY, SanGiovanni JP, Ferris III FL, Wong WT, Agron E et al. Age-Related Eye Disease Study 2 Research Group. Lutein/ zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. Journal of American Medical Association of Ophthalmology 2013; 131 (7): 843-850. doi: 10.1001/jamaophthalmol.2013.4412
17. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B et al. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. Journal of American Medical Association 2007; 297 (16): 1793-1800. doi: 10.1001/jama.297.16.1793
18. Lesher AM, Nilsson B, Song W-C. Properdin in complement activation and tissue injury. Molecular Immunology 2013; 56 (3): 191-198. doi: 10.1016/j.molimm.2013.06.002
19. Fox AR, Chew EY, Meyerle C, Vitale S, Ferris FL et al. Agerelated macular degeneration in patients with uveitis. British Journal of Ophthalmology 2017; 101 (3): 342-347. doi: 10.1136/ bjophthalmol-2016-308587
20. Clark SJ, Ridge LA, Herbert AP, Hakobyan S, Mulloy B et al. Tissue-specific host recognition by complement factor H 496 is mediated by differential activities of its glycosaminoglycanbinding regions. Journal of Immunology 2013; 190 (5): 2049- 5207. doi: 10.4049/jimmunol.1201751
21. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Control Clinical Trials 1999; 20 (6): 573-600. doi: 10.1016/s0197-2456(99)00031-8
22. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proceedings of the National Academy of Sciences of the USA 1992; 89 (21): 9991-9995. doi: 10.1073/ pnas.89.21.9991
23. Cruz-Guilloty F, Saeed AM, Duffort S, Cano M, Ebrahimi KB et al. T cells and macrophages responding to oxidative damage cooperate in pathogenesis of a mouse model of age-related macular degeneration. Public Library of Science One 2014; 9 (2): e88201. doi: 10.1371/journal.pone.0088201
24. Choudhary M, Safe S, Malek G. Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor. Biochimica et Biophysica Acta - Molecular Basis of Disease 2018; 1864 (5 Pt. A): 1583-1595. doi: 10.1016/j.bbadis.2018.02.015
25. Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernandez P et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheumatology 2007; 56: 1440-1445.
26. Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K . Inflammation and its role in age-related macular degeneration. Cellular and Molecular Life Sciences 2016; 73: 1765-1786. doi: 10.1007/s00018-016-2147-8
27. Vavvas DG, Daniels AB, Kapsala ZG, Goldfarb JW, Ganotakis E et al. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. EBioMedicine 2016; 5: 198-203. doi: 10.1016/j.ebiom.2016.01.033
28. Roizenblatt M, Naranjit N, Maia M, Gehlbach PL. The question of a role for statins in age-related macular degeneration. International Journal of Molecular Sciences 2018; 19 (11): 3688. doi: 10.3390/ijms19113688.
29. Li JQ, Welchowski T, Schmid M, Julia Letow J, Wolpers AC et al. Retinal diseases in Europe. European Society of Retina Specialists (EURETINA) 2017.
30. Silva R, Berta A, Larsen M, Macfadden W, Feller C et al. TREND Study Group. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND Study. Ophthalmology 2018; 125 (1): 57-65. doi: 10.1016/j. ophtha.2017.07.014
31. Reich O, Schmid MK, Rapold R, Bachmann LM, Blozik E. Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland. BioMed Central Ophthalmology 2017; 17 (234). doi: 10.1186/s12886-017-0617-x
32. Van Asten F, Michels CTJ, Hoyng CB, Van der Wilt GJ, Klevering BJ et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—a cost-effectiveness analysis from a societal perspective. Public Library of Science One 2018; 13 (5): e0197670. doi: 10.1371/journal.pone.0197670
33. Souliotis K, Golna C, Kani C, Nikolaidi S, Boumpas D. Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece. Public Library of Science One. 2019; 14 (12): e0226287. doi: 10.1371/journal.pone.0226287
34. Schnabolk G, Rohrer B, Simpson KN. Increased nonexudative age-related macular degeneration diagnosis among medicare beneficiaries with rheumatoid arthritis. Investigative Ophthalmology and Visual Sciences 2019; 60 (10): 3520-3526. doi: 10.1167/iovs.18-26444
35. Villegas Becerril E, González Fernández R, Pérula Torres L, Lacomba MS, Gallardo et al. HLA B27 as predisposition factor to suffer age related macular degeneration. Cellular and Molecular Immunology 2009; 6 (4): 303-307. doi: 10.1038/ cmi.2009.40
36. Bergen AA, Arya S, Koster C, Pilgrim MG, WiatrekMoumoulidis D et al. On the origin of proteins in human drusen: the meet, greet and stick hypothesis. Progress in Retinal and Eye Research 2019; 70: 55-84. doi: 10.1016/j. preteyeres.2018.12.003